EBR Systems to Present at Canaccord Genuity MedTech Forum on 11 November 2026

Manish Choudhary

03 November 2026 08:45 PM AEDT

EBR Systems to Present at Canaccord Genuity MedTech Forum on 11 November 2026

Image Source: Krish Capital Pty Ltd

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

EBR Systems, Inc. (ASX:EBR), developer of a wireless cardiac pacing device for heart failure, has disclosed that company management will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on Wednesday, 11 November 2026, at The Westin Grand Central in New York, NY.

Key Points

EBR Systems management will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on 11 November 2026
The event will be held at The Westin Grand Central in New York, NY
EBR Systems describes itself as the developer of the world's only wireless cardiac pacing device for heart failure
The announcement was authorised for release by the Routine Disclosure Committee, a Committee of the Board

Presentation Details at Canaccord Genuity MedTech Forum

According to the filing, EBR Systems management is scheduled to present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on Wednesday, 11 November 2026. The presentation will take place at The Westin Grand Central, located in New York, NY. The company is headquartered in Santa Clara, California, and its CHESS Depositary Interests (CDIs) are traded on the ASX under the ticker EBR. No further details regarding the content of the presentation were disclosed in the filing.

EBR Systems' WiSE Technology

EBR Systems states that its patented Wireless Stimulation Endocardially (WiSE) technology is the world's only wireless, endocardial pacing system in clinical use for stimulating the heart's left ventricle. The technology features a cardiac implant described as roughly the size of a large grain of rice. According to the filing, WiSE technology was developed to eliminate the need for cardiac pacing leads, historically a major source of complications in cardiac rhythm disease management. The filing states that WiSE is an investigational device in most markets and is currently only available for sale in the US.

CDI Foreign Ownership Restrictions

The filing discloses that EBR's ASX-traded CDIs are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 for offers or sales made outside the US. The CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. Holders of EBR's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.